Lifevantage Corporation · NASDAQ:LFVN
Lifevantage — Investor Presentation (September 2025)
37 slides from Lifevantage's investor presentation, September 2025
Slide 1: Mission
MISSION: W E O F F E R P E O P LE A R O U ND T H E W O R LD A B E T T E R P A T H T O W E LLN E S S A N D A H E A LT H Y V I B R A N T LI F E .
Slide 2: Forward Looking Statements
Forward Looking Statements SAFE HARBOR STATEMENT This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects
Slide 3: LifeVantage Fact Sheet
LifeVantage Fact Sheet NASDAQ Ticker LFVN Share price1 $13.46 Shares outstanding1 12.4 million Float1 9.9 million Market Capitalization1 $167.0 million Enterprise Value1 $146.8 million Average Daily Volume1 104,225 Fiscal 2025 Revenue $228.5 million Cash at June 30, 2025 $20.2 million Fiscal 2025 Ad
Slide 4: LifeVantage At a Glance
LifeVantage At a Glance • Pioneer in Activation and nutrigenomics with patented, scientifically validated products that work with your unique biology and help your body make what it needs for health • Direct Sales industry-leader with sales force of independent Consultants and approximately 132,000
Slide 5: The Activation Company
The Activation Company ACTIVATING WELLNESS AROUND THE WORLD THROUGH DIRECT SALES Working in partnership with thousands of Independent Consultants around the world, LifeVantage, the Activation Company, activates many aspects of wellness. We ACTIVATE physical wellness, inside and out, with products th
Slide 6: Optimal Position for Direct Sales Industry
Optimal Position for Direct Sales Industry ADDRESSING THE TWO LARGEST CATEGORIES IN THE LARGEST MARKETS LIFEVANTAGE OPERATES IN 6 OF THE 10 LARGEST DIRECT SELLING MARKETS GLOBALLY INVESTOR PRESENTATION 6 See the Sales by Product Category Report here: https://heyzine.com/flip-book/WFDSASTATS2024#page
Slide 7: Activation Around the Globe
Activation Around the Globe LIFEVANTAGE PERCENTAGE OF SALES BY AREA $167.7 Billion Industry* Europe 22% 3% Americas 37% Europe 79% Africa/ME Asia Pacific USA, Canada, 1% 40% Puerto Rico, Mexico 18% Japan, Taiwan, Hong Kong, Singapore, Thailand, New Zealand, Australia, *Source: World Federation of Di
Slide 8: Acquisition of LoveBiome
Acquisition of LoveBiome • Leader in the emerging microbiome health sector • Started in 2022 • Driven by a mission to help people live long, healthy meaningful lives through superior and innovative microbiome care. • Desire to be the most advanced approach to microbiome health on the market led to t
Slide 9: The Activation Approach - Take It To Make It
T H I S I S A S U B - H E A D IN G The Activation Approach - Take It To Make It As the years go by, the toll of time, the environment, and daily choices add up. Most turn to supplements to fill the voids left by modern life. But the truth is, supplements meet basic needs but often fall short when it
Slide 10: Protandim Nrf2 Antioxidants
TAKE IT Protandim Nrf2 ® MAKE IT Antioxidants Oxidative stress is a key contributor to the signs of aging, and Protandim Nrf2 Synergizer is the only supplement shown to reduce oxidative stress by 40% in just 30 days. Support your body’s own production of powerful antioxidants to fight the signs of a
Slide 11: Healthy Glow Essentials Antioxidants, Collagen
TAKE IT Healthy Glow Essentials MAKE IT Antioxidants, Collagen Life is hard on your body. You need antioxidants to fight stress, stay balanced and recover. You need collagen support because it's crucial and your body stops making enough in your early 20’s. Do nothing and let life and aging process t
Slide 12: MindBody GLP-1 System GLP-1
TAKE IT MindBody GLP-1 System MAKE IT GLP-1 This innovative, patent-pending System is clinically shown to naturally increase GLP-1 by an average of 200% as it balances hunger hormones—no injections or prescriptions required. Build better habits, achieve your ideal weight, and become a stronger, heal
Slide 13: Transformative, Patent-Pending Results
Transformative, Patent-Pending Results Key findings from U.S. clinical studies on the MindBody GLP-1 SystemTM include: • Over 200% average increase in GLP-1 over 12 weeks‡‡ • Average weight loss of 11 pounds within 12 weeks, with some participants losing up to 25 pounds‡,‡‡ • Up to 9% decrease in to
Slide 14: A Natural Approach
A Natural Approach What is GLP-1? GLP-1 (Glucagon-like Peptide – 1) is a hormone produced naturally in the lower GI tract. It regulates appetite and blood sugar levels, while slowing down the rate at which food leaves the stomach. GLP-1 communicates with the brain along the brain-gut axis to promote
Slide 15: Understanding the Weight Loss Market
Understanding the Weight Loss Market GLP-1 MARKET OVERVIEW In recent years, drugs including those classified as semiglutides and tirzepatides, have not only changed the approach to diabetes treatments, but obesity and weight management as well. This broad class of drugs work by mimicking hormones th
Slide 16: LoveBiome P84 Gut Peptides
TAKE IT LoveBiome P84 MAKE IT Gut Peptides Your gut plays an essential role. Often referred to as your second brain, it's in constant communication to ensure your entire body is functioning properly. However, your gut gets hit hard with daily attacks from your environment, diet, lifestyle and aging
Slide 17: Gut Health: A $32B Market Opportunity Transforming Global Wellness
Gut Health: A $32B Market Opportunity Transforming Global Wellness The gut health market represents one of the most exciting frontiers in wellness and preventive care, with strong momentum and long-term growth potential. Global gut health supplement sales are projected to reach $14.4 billion in 2025
Slide 18: Stacks + Subscriptions for Health Synergies — Inside and Out
Stacks + Subscriptions for Health Synergies — Inside and Out We offer several product stacks designed for Subscription. Each provides a unique health solution by delivering activation synergies when the products are used together. Consumers save on products and see and feel even more benefits while
Slide 19: Modernized Compensation Plan Attracts Independent Business Owners
Modernized Compensation Plan Attracts Independent Business Owners Our new Evolve Compensation Plan helps Consultants activate financial wellness and evolve possibilities in their lives. They can choose to earn supplemental income solely through Customer sales or also by building a team of Consultant
Slide 20: History & Focus for the Future
HISTORY & FOCUS FOR THE FUTURE 20
Slide 21: Significant Progress with Key Strategic Initiatives
Significant Progress with Key Strategic Initiatives PRO DUCT / PLATFO RM DEVELO PM ENT / CAPI TAL ALLO CATI O N INVESTOR PRESENTATION
Slide 22: Laser-Focused on the Experience
Laser-Focused on the Experience Since the launch of LV360 initiatives in 2023, LifeVantage has been laser- focused on increasing active monthly purchasers - enrolling new business builders and Customers, and retaining them longer - by focusing on six elements of our direct sales business – product,
Slide 23: Financial Overview
Financial Overview INVESTOR PRESENTATION
Slide 24: Business Model
Business Model LIFEVANTAGE Long-term (as % of revenue) FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 Target Gross Margin 82.7% 81.5% 79.7% 79.3% 80.4% 80.0% Commissions and Incentives 47.0% 47.1% 44.4% 42.9% 44.7% 43.0% SG&A* 26.9% 30.7% 32.9% 31.3% 29.8% 28.0% Operating Margin* 8.7% 3.7% 2.4% 5.0% 5.8% 9
Slide 25: Revenues
Revenues Revenue (USD in thousands) $300,000 $250,000 $200,000 • FY25 revenue increased 14.2% vs. FY24 • The midpoint of our FY26 revenue guidance of $150,000 $225 million to $240 million represents a 2% increase over FY25 $100,000 $50,000 $- 2023 2024 2025 2026E INVESTOR PRESENTATION 25
Slide 26: Revenues by Geography
Revenues by Geography Revenue (USD in thousands) $250,000 $24,694 $200,000 $32,793 $27,496 $25,394 $32,083 $26,989 • Currently selling products in 20 countries $150,000 • USA largest market at 78% in FY25 $100,000 $178,442 • Japan next largest at 11% in FY24 $148,522 $145,679 $50,000 $- 2023 2024 20
Slide 27: Strong Balance Sheet
Strong Balance Sheet (USD in thousands) June 30, 2025 June 30, 2024 Cash and Cash Equivalents $ 20,201 $ 16,886 • Debt Free Inventory 20,669 15,055 Total Current Assets 50,894 37,646 • $23.7 MM in working capital at 6/30/25 Total Assets $ 71,958 $ 60,299 • Clean Equity – only one class of common sha
Slide 28: Robust Capital Allocation Priorities Deliver…
Robust Capital Allocation Priorities Deliver… CASH FROM OPERATIONS Invest in Growth Return Value to Stockholders • Dividends • Expand Capabilities • Current quarterly dividend $0.045/share • Special dividend of $0.40/share (Sep’23) • New Product Development • Paid $9.5M in dividends since the beginn
Slide 29: …Strong Shareholder Returns
…Strong Shareholder Returns 1-Year Total Shareholder Return 3-Year Total Shareholder Return LifeVantage 72% LifeVantage 295% Peer Group Median Peer Group Median Russell 2000 Russell 2000 0% 10% 20% 30% 40% 50% 60% 70% 80% -80% 0% 80% 160% 240% 320% INVESTOR PRESENTATION 29 Source: Factset as of 9/2/
Slide 30: Summary
Summary LIFEVANTAGE Well-positioned with on-trend, scientific products in a growing, global sales channel Continuous focus on product innovation, international market expansion, and positive experiences Subscription-based business model with strong cash flow and high incremental margins Modern busin
Slide 31: Appendix
Appendix INVESTOR PRESENTATION
Slide 32: Recent Operating Results Comparison
Recent Operating Results Comparison LI FEVANTAG E CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Year over Previous Sequential Sequential Most Recent Quarter Prior Year Period Year Quarter Change Change (In thousands, except per share data) Q4 of Fiscal 2025 Q4 of Fiscal 2024 % Q3 of Fi
Slide 33: Historical Income Statements
Historical Income Statements LI FEVANTAG E CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Fiscal Year ended June 30, (In thousands, except per share data) 2023 2024 2025 Revenue, net $ 213,398 $ 200,164 $ 228,530 Cost of sales 43,387 41,440 44,864 Gross profit 170,011 158,724 183,666 Co
Slide 34: Historical Balance Sheet and Cash Flows
Historical Balance Sheet and Cash Flows LI FEVANTAG E SUMMARIZED BALANCE SHEET AND CASH FLOW METRICS As of June 30, (Unaudited, in thousands, except per share data) 2023 2024 2025 Cash and Cash Equivalents $ 21,605 $ 16,886 $ 20,201 Current Portion of Long-term Debt, net - - - Net Cash (Cash and equ
Slide 35: Non-GAAP Reconciliations
Non-GAAP Reconciliations LI FEVANTAG E Adjusted Net Income Three Months ended (Unaudited, in thousands, except per share data) Fiscal Year ended June 30, June 30, 2023 2024 2025 2024 2025 GAAP net income $ 2,540 $ 2,937 $ 9,805 $ 1,305 $ 1,959 Adjustments: Executive team recruiting and transition ex
Slide 36: Non-GAAP Reconciliations
Non-GAAP Reconciliations LI FEVANTAG E EBITDA and Adjusted EBITDA Three Months ended (Unaudited, in thousands) Fiscal Year ended June 30, June 30, 2023 2024 2025 2024 2025 GAAP net income $ 2,540 $ 2,937 $ 9,805 $ 1,305 $ 1,959 Interest (income) expense (198) (430) (431) (78) (111) Provision for inc
Slide 37: Investor Presentation
Park gou INVESTOR PRESENTATION 37